Boehringer Ingelheim and the BioMed X Innovation Center, a biomedical research center in Heidelberg, Germany, applied crowdsourcing to develop a research team of early career scientists who will work to identify new approaches in treating chronic obstructive pulmonary disease (COPD).

The team will focus on the characterization of epigenetic regulators of the COPD pathophysiology. Epigenetics is defined as heritable changes in gene expression or phenotype that do not involve a change in the underlying DNA sequence.

The research will take place in the BioMed X Innovation Center located on the campus of the University of Heidelberg. The team will be sponsored by Boehringer Ingelheim for two years with the option to extend the funding period up to a total of four years.

Source: Boehringer Ingelheim